Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
US-10221245-B2 · Mar 5, 2019 · US
Compositions and methods for treating b-lymphoid malignancies
US2017239294A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017239294-A1 |
| Application number | US-201515519323-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 15, 2015 |
| Priority date | Oct 15, 2014 |
| Publication date | Aug 24, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of inhibiting a B-cell neoplasm in a subject in need thereof, wherein said B-cell neoplasm expresses a CD19 isoform, said method comprising administering to the subject a therapeutically effective amount of at least one Src family kinase (SFK) inhibitor and/or at least one chimeric antigen receptor-modified T cell which recognizes the ectodomain of said CD19 isoform, CD20, or CD22. 2 . The method of claim 1 , wherein said B-cell neoplasm is a lymphoma or B-cell acute lymphoblastic leukemia. 3 . The method of claim 1 , wherein said B-cell neoplasm is a relapse after CART19 therapy. 4 . The method of claim 1 , comprising administering to the subject a therapeutically effective amount of a Src family kinase (SFK) inhibitor. 5 . The method of claim 4 , wherein said SFK inhibitor is a Lyn inhibitor. 6 . The method of claim 4 , wherein said SFK inhibitor is dasatinib. 7 . The method of claim 1 , further comprising the administration of at least one other chemotherapeutic agent or radiation therapy to the subject. 8 . The method of claim 1 , comprising administering to the subject at least one chimeric antigen receptor-modified T cell which recognizes the ectodomain of said CD19 isoform, CD20, or CD22. 9 . The method of claim 8 , comprising administering to the subject a chimeric antigen receptor-modified T cell which recognizes the ectodomain of said CD19 isoform. 10 . The method of claim 1 , wherein said CD19 isoform comprises a deletion of exon 2, 5, and/or 6. 11 . The method of claim 1 , wherein said B cell neoplasm does not substantially express wild-type CD19. 12 . The method of claim 9 , wherein said CD19 isoform comprises a deletion of exon 2, 5, and/or 6. 13 . The method of claim 12 , wherein said CD19 isoform comprises a deletion of exon 2. 14 . The methods of claim 1 , wherein said method further comprises determining the isoform of CD19 expressed by the B-cell neoplasm prior to treatment of the subject.
Assignees
Inventors
Classifications
- A61K45/06Primary
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Cells of blood, e.g. leukemia cells, myeloma cells · CPC title
- A61K31/506Primary
not condensed and containing further heterocyclic rings · CPC title
- A61K35/17Primary
Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title
Molecules with a "CD" designation not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017239294A1 cover?
- Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided.
- Who is the assignee on this patent?
- The Children'S Hospital Of Philadelphia, Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Aug 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).